Laura Devis-Jauregui, August Vidal, Laura Plata-Peña, Maria Santacana, Sandra García-Mulero, Nuria Bonifaci, Eulàlia Noguera-Delgado, Nuria Ruiz, Marta Gil, Eduard Dorca, Francisco J Llobet, Laura Coll-Iglesias, Katja Gassner, Maria Martinez-Iniesta, Ruth Rodriguez-Barrueco, Marc Barahona, Lola Marti, Francesc Viñals, Jordi Ponce, Rebeca Sanz-Pamplona, Josep M Piulats, Ana Vivancos, Xavier Matias-Guiu, Alberto Villanueva, David Llobet-Navas
Clinical management of endometrial cancer (EC) is handicapped by the limited availability of second line treatments and bona fide molecular biomarkers to predict recurrence. These limitations have hampered the treatment of these patients, whose survival rates have not improved over the last four decades. The advent of coordinated studies such as The Cancer Genome Atlas Uterine Corpus Endometrial Carcinoma (TCGA_UCEC) has partially solved this issue, but the lack of proper experimental systems still represents a bottleneck that precludes translational studies from successful clinical testing in EC patients...
November 14, 2022: Advanced Science (Weinheim, Baden-Wurttemberg, Germany)